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2Summary The anticancer agent cis-diamminedichloroplatinum (cisplatin) is a first-line 
chemotherapeutic agent for oral cancer. Cell exposure to cisplatin is associated with
increased oxidative stress and post-translational changes in components of apoptosis 
pathways, including p38 Mitogen-activated protein kinase (MAPK), c-Jun-NH2-kinase 
(JNK), and extracellular signal-regulated kinase (ERK). Peroxiredoxin (Prx) I is an 
oxidative stress-inducible protein expressed in many tissues and important for reducing 
reactive oxygen species in vivo; however, whether Prx I helps protect cells from 
cisplatin injury is unknown. In this report, we examined the effects of Prx I on cell
sensitivity to cisplatin-induced apoptosis. Mouse embryo fibroblasts (MEFs) derived 
from Prx I-deficient mice showed increased cisplatin-induced apoptosis compared with 
wild-type MEFs. Cisplatin treatment also led to increased activation of p38 MAPK and 
JNK, and reduced ERK phosphorylation in Prx I-deficient MEFs compared with 
wild-type MEFs. Furthermore, JNK- and ERK-specific inhibitors protected the Prx 
I-deficient MEFs from cisplatin-induced apoptosis, but Prx I-deficient MEFs remained 
more sensitive than wild-type MEFs when treated with a p38 MAPK-specific inhibitor.
These findings indicate that Prx I modulates the cisplatin-evoked activation of MAPKs
that lead to apoptosis, and Prx I may thus represent a useful target as a protective 
therapy against cisplatin cytotoxicity.
3Introduction
Cisplatin is widely used as a first-line therapy against malignant tumors 1, 2, and 
cisplatin-based chemotherapy is the central component of several curative approaches 
for patients with head and neck cancer 3. Despite its high efficacy, however, its usage is 
limited by its cytotoxicity, especially nephrotoxicity, which requires lowing its dosage 
or actively hydrating patients 4. Thus, it is very important to discover mechanisms to 
prevent or attenuate cisplatin toxicity.
The molecular mechanisms underlying cisplatin toxicity were recently clarified. 
One is oxidative stress. Cisplatin treatment increases the level of reactive oxygen 
species (ROS), which trigger cisplatin-induced apoptosis 5. Cisplatin induces ROS in 
vitro by decreasing the activity of antioxidant enzymes and depleting the intracellular 
concentration of GSH. Antioxidants help protect cells from cisplatin-induced apoptosis 
in vitro. In vivo, antioxidants reduce the degree of renal failure caused by cisplatin1. 
However, the potential benefits of using an endogenous antioxidant protein, 
Peroxiredoxin (Prx), to block Cisplatin-induced cytotoxicity have not been evaluated 
extensively. 
Members of the Prx family catalyze the reduction of H2O2, alkyl hydroperoxides, 
and radicals via the reducing equivalents provided by thiol-containing proteins, such as 
thioredoxin 6-9. There are currently six Prx family members, which share a common 
reactive Cys residue in the N-terminal region. Prx I is the major cytosolic Prx; it is 
ubiquitously expressed in various tissues 10. 
We previously used a Prx I-deficient mouse to investigate the anti-oxidative 
activities of Prx I against ferric-nitrilotriacetate (Fe-NTA)-induced oxidative stress and 
its scavenging of radicals in the kidney and liver, using real-time electron paramagnetic 
resonance imaging. We detected greater damage in the liver and kidney of Prx 
I-deficient mice than wild-type mice, suggesting that the Prx I deficiency decreased the 
anti-oxidative activities in these organs 10. In the present study, we found that Prx 
I-deficient mouse embryo fibroblast cells (MEFs) were more sensitive to cisplatin than 
wild-type MEFs. We then investigated the apoptotic signaling components in the Prx 
I-deficient MEFs, and showed that Prx I interfered with cisplatin-induced apoptosis by 
modulating the mitogen-activated protein kinase (MAPK)-associated pathways. 
4Materials and methods
Cell Culture and Treatment 
Homozygous Prx I-deficient (Prx I (-/-)) (OmniBank, Lexicon Pharmaceuticals, Inc.)
and wild-type (Prx I (+/+)) mice were treated as described previously 10. 
Non-immortalized MEFs were generated from 13.5-day Prx I (-/-) and Prx I (+/+) 
embryos. The brain and dark-red (internal) organs were dissected away from the 
embryos, and the remaining tissue was finely minced. The cells were disaggregated 
using 0.25% trypsin, which was removed by centrifugation. The cells were cultured at 
37 C in 95% air 5% CO2 as an adherent monolayer in Dulbecco's Modified Eagle's 
Medium (DMEM) with 10% fetal bovine serum (FBS) containing penicillin (100 U/ml) 
and streptomycin (100 µg/ml). Cisplatin was purchased from Sigma (Sigma Aldrich 
Japan, K.K., Tokyo). The MAPK-specific inhibitors SB203580, SP600125, and 
PD98059 were purchased from Wako (Wako Pure Chemical Industries, Osaka).
Cytotoxicity assays
Cell viability was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-zolium 
bromide (MTT) assay as described previously 11. Cells (5 x 103/well) were seeded in 
96-well plates and incubated at 37 C overnight. Following exposure to increasing 
concentrations of cisplatin for 3 days at 37 C, MTT was added, and the cells were 
incubated for 4 hours at 37 C. The absorbance at 540 nm was determined using a 
Varioskan (ThermoFisher Scientific K.K., Yokohama). Cytotoxicity was expressed as 
the ratio of the absorbance of the cisplatin-treated cells to that of the untreated cells.
Flow Cytometry Analysis
The apoptosis in Prx I(-/-) and Prx I(+/+) MEFs was assessed using an Annexin 
V–FLUOS Staining Kit (Roche Diagnostics K.K., Tokyo) followed by flow cytometry. 
Cells were seeded at 1 x 105 cells per 35-mm dish, grown overnight in 10% 
FBS/DMEM, and then treated for 24, 48, or 72 hours with 5 g/ml cisplatin. The 
resuspended cells were stained with a fluorescein isothiocyanate (FITC)-conjugated 
5Annexin V antibody and propidium iodide (PI), according to the instructions provided 
by the manufacturer. The cells (2 x 104 per sample) were then analyzed using a flow 
cytometer (FACS Calibur; Becton Dickinson co., Tokyo) equipped with a 488-nm argon 
laser and Cell Quest Pro software.
Western blot analysis
Proteins were electrophoretically resolved in polyacrylamide gels and transblotted onto 
PVDF membranes. The polyclonal antibodies against Prx I were described previously 12. 
The antibodies against p-p38, p38, p-Erk1/2, Erk1/2, p-JNK, and JNK were purchased 
from Cell Signaling Technology (Cell Signaling Technology Japan, K.K., Tokyo), and 
the anti-actin antibody was purchased from Sigma Aldrich (Sigma Aldrich Japan, K.K., 
Tokyo). The protein-antibody complexes were detected using an ECL plus kit (GE 
Healthcare Bio-Sciences K.K., Tokyo). The intensity of the protein bands was 
determined using the ImageJ Analysis software 1.41o (Wayne Rasband, National 
Institutes of Health, Bethesda). 
Statistical analysis
All data are presented as the mean ± SD. Differences among data were determined 
using Student’s t-test (StatView, version 5.0, Abacus Concepts, Berkeley). 
Results
Loss of Peroxiredoxin I alters the cells’ sensitivity to cisplatin. 
First, we examined the effect of Prx I expression on the cells’ sensitivity to cisplatin. 
For these studies, we used Prx I (-/-) and Prx I (+/+) MEFs obtained from 13.5-day-old 
embryos. Prx I (+/+) and Prx I (-/-) MEFs were exposed to various concentrations of 
cisplatin for 72 hours, and cell survival was determined by the MTT assay. Fig. 1 shows 
the cell viability of cisplatin-treated Prx I (+/+) and Prx I (-/-) MEFs. Prx I (-/-) MEFs 
were more sensitive to cisplatin at concentrations of 5 g/ml (P<0.001), and 10 g/ml 
6(P<0.001) after 72 hours.
Enhanced sensitivity of Prx I-deficient cells to cisplatin is owing to 
apoptosis
We performed FACS analyses to confirm whether the measured increase in the 
sensitivity of the Prx I-deficient MEFs to cisplatin was owing to cisplatin-induced 
apoptosis. The upper panels in Fig. 2A show untreated and cisplatin-treated Prx I (+/+) 
MEFs. The lower panels show the results for Prx I (-/-) MEFs subjected to the same 
treatments. There were more dots in the lower-right quadrant for the cisplatin-treated 
Prx I (-/-) MEFs than for the similarly treated Prx I (+/+) MEFs, suggesting that the Prx 
I (-/-) MEFs were predisposed to undergo apoptosis. Fig. 2B shows the quantification of 
the FACS analysis. The percentage of cells that appeared in the upper- and lower-right 
quadrants was used as the apoptosis ratio. Twenty-four hours after cisplatin exposure, 
26.1% of the Prx I (-/-) cells were apoptotic, compared with only 17.5% of the Prx I 
(+/+) cells, a significant difference (P < 0.01). The proportion of apoptotic cells 
increased with time in culture for both groups of cisplatin-treated cells. After 48 hours 
of cisplatin exposure, 74.3% of the Prx I (-/-) cells were apoptotic, a significant increase 
compared with the 30.1% of Prx I (+/+) cells that were apoptotic (P < 0.001). After 72 
hours of cisplatin exposure, 89.1% of the Prx I (-/-) cells were apoptotic, compared with 
only 43.5% of the Prx I (+/+) cells (P < 0.001). These results indicate that the Prx I (-/-) 
MEFs were more susceptible to cisplatin-induced apoptosis than the Prx I (+/+) MEFs. 
Differential mitogen-activated protein kinase activation by cisplatin in Prx 
I-deficient cells
Previous reports indicate that the apoptotic signaling induced by cisplatin is conducted 
through MAPKs. There are three major pathways involving MAPKs: the 
c-Jun-N-terminal kinase (JNK), p38 MAP kinase, and extracellular signal-regulated 
kinase (ERK) pathways 13. We therefore examined the effect of Prx I loss on the 
activation of MAPKs following exposure to cisplatin. 
As shown in Fig. 3A, exposure to cisplatin induced greater p38 MAPK 
7phosphorylation in the Prx I (-/-) MEFs than the control Prx (+/+) MEFs, while the total 
p38 MAPK protein level remained similar between the two groups. Fig. 3B shows the 
ratio of the phosphorylated p38 MAPK to p38 MAPK. The basal level of p38 MAPK 
phosphorylation in the Prx I (-/-) MEFs was lower than in the Prx I (+/+) MEFs, and the 
p38 MAPK activation in the Prx I (-/-) MEFs was greater than in the Prx I (+/+) MEFs 
at the 1- and 2-hour time points. JNK activation was also elevated in the Prx I (-/-) 
MEFs, and the ratio of phosphorylated JNK to JNK was significantly increased at the 
2-hour time point (Fig. 3C, D). On the other hand, exposure to cisplatin induced 
ERK1/2 phosphorylation in the control Prx I (+/+) MEFs but not in the Prx I (-/-) MEFs 
(Fig. 3E, F). Thus, the loss of Prx I in cells is associated with increased 
cisplatin-induced p38 MAPK and JNK signaling, and reduced ERK signaling.
Cisplatin-induced apoptosis is attenuated by MAPK inhibitors 
We therefore examined which MAPK activation was critical for cisplatin-induced 
apoptosis by using MAPK-specific inhibitors. We used the p38 MAPK inhibitor 
SB203580, the JNK inhibitor SP600125, and the ERK inhibitor PD98059, and 
examined the cisplatin-induced apoptosis in Prx I (-/-) and Prx I (+/+) MEFs by FACS. 
Fig. 4A shows typical FACScalibur results from cultures treated with inhibitors, 
and Fig. 4B shows the quantification of the FACS analysis. The percentage of cells 
appearing in the upper- and lower-right quadrants was used as the apoptosis ratio. After 
cisplatin exposure, 65.6% of the Prx I (-/-) cells were in the upper- and lower-right 
quadrants, i.e. in the early and late stages of apoptosis, whereas only 48.1% of the Prx I 
(+/+) MEFs were apoptotic under the same conditions. SB203580 reduced the 
cisplatin-induced apoptosis in Prx I (-/-) cells (††P < 0.01), but did not significantly 
affect it in Prx I (+/+) MEFs. After treatment with cisplatin and 10 M SB203580, 
apoptosis was observed in 51.7% of the Prx I (-/-) cells and 39.2% of the Prx I (+/+) 
cells, a significant difference (**P<0.01). 
In the case of the JNK inhibitor, SP600125, the percentage of apoptotic 
SP600125-treated Prx I (-/-) and Prx I (+/+) cells was significantly reduced compared 
with cisplatin treatment alone (#P < 0.05, †††P < 0.001, respectively), and there was no 
difference in the apoptosis ratio between the Prx I (-/-) and Prx I (+/+) MEFs. These 
results indicate that SP600125 blocked the specific apoptotic signal that Prx I modulates. 
8Similar results were obtained using the ERK inhibitor PD98059. That is, the percentage 
of apoptotic PD98059-treated Prx I (-/-) and Prx I (+/+) cells was reduced significantly 
compared with cisplatin treatment alone (##P < 0.01, †††P < 0.001, respectively), and 
PD98059 also eliminated the difference in cisplatin-induced apoptosis between the Prx I 
(-/-) and Prx I (+/+) MEFs. These results indicate that the increased cisplatin-induced 
apoptosis in the Prx I (-/-) MEFs mainly depended on JNK and ERK signaling, whereas 
p38 MAPK may be activated independent of the apoptotic signaling that is modulated 
by Prx I. 
Discussion
Our results showed that Prx I (-/-) MEFs were more sensitive to cisplatin than Prx I 
(+/+) MEFs, and this difference was due to increased apoptosis. MAPKs are critical 
components of the intracellular signaling networks that regulate gene expression in 
response to cisplatin, and MAPK activation determines the fate of cells in response to 
this drug 13. The three major pathways involving MAPKs are the JNK, p38 kinase, and 
ERK pathways. We observed that cisplatin treatment enhanced the phosphorylation of 
p38, MAPK, and JNK, and suppressed the phosphorylation of ERK1/2 in Prx I (-/-) 
MEFs (Fig. 3). Furthermore, the JNK inhibitor SP600125 and ERK inhibitor PD98059 
eliminated the difference in the apoptotic ratio between the Prx I (-/-) and Prx I (+/+) 
MEFs, but the p38 MAPK inhibitor SB203580 did not. These findings suggest that the 
apoptotic signals mediated by JNK were enhanced by cisplatin, whereas those mediated 
by ERK were reduced by it, in the Prx I (-/-) cells. On the other hand, although p38 
MAPK was activated in the Prx I (-/-) cells, it is unclear that its activation was directly 
associated with the cisplatin-induced apoptosis. Our findings suggest that Prx I 
modulates the apoptosis signal negatively via JNK and positively via ERK, but that p38 
MAPK activation may not be modulated by Prx I in cisplatin-induced apoptotic 
signaling. 
Prx I was first cloned as an oxidative stress-induced protein 12, 14, and one of its 
functions is to eliminate hydrogen peroxide and hydroxyl radicals 8, 9, 15-18. In this 
experiment, oxidative cisplatin treatment also induced marked Prx I expression within 8 
hr (Supplemantary Fig. 1). Several reports have described substances that bind to Prx I, 
and among them are two candidate factors for cisplatin sensitivity: c-Abl and ASK1 
9(Apoptosis signal-regulating kinase 1). 
PAG, the human counterpart of Prx I, binds to the SH3 domain of c-Abl and 
inhibits c-Abl’s kinase activity and cytostatic function; it is also a physiological 
inhibitor of c-Abl19 20. c-Abl is activated in response to oxidative stress, and oxidative 
stress-induced apoptosis is attenuated in c-Abl-deficient fibroblasts, supporting a 
pro-apoptotic role for c-Abl in the oxidative stress response 21-23. Furthermore, c-Abl 
functions upstream of JNK in response to cisplatin 24. Considering these findings, we 
hypothesize that the cisplatin-induced apoptotic signal that enhances the activation of 
c-Abl is mediated by oxidative stress, and that Prx I may modulate the apoptotic signal 
by acting as a physiological inhibitor of c-Abl.
ASK1 is a MAP kinase kinase kinase (MAPKKK) that is thought to be a major 
player in cisplatin sensitivity. Thioredoxin (TRX), which interacts with ASK1, is a 
sensor for oxidative stress and helps to protect tissues from oxidative stress-associated 
damage 25. In vitro, cisplatin activates ASK1, and subsequently, its downstream 
subgroups SEK1 (or MKK4), and MKK3/MKK6, which in turn activate JNK and p38 
MAPK, prior to the onset of apoptosis 26. Recently, Kim et al. reported that Prx I 
interacts with the TRX-binding domain of ASK1 and helps to inhibit ASK1-induced 
apoptosis 27. Thus, we can hypothesize that one of the major sites of Prx I action in the 
cisplatin-induced apoptosis pathways is its interaction with ASK1.
In our study, ERK activation was suppressed in Prx I (-/-) MEFs, but apoptosis was 
enhanced in them. ERK can upregulate either apoptosis or cell survival by multiple 
mechanisms, including by increasing p53 and BAX activities, increasing caspase-3 and 
caspase-8 activities, decreasing Akt activity, and increasing TNFα production 28. 
Therefore, if Prx I modulates a specific pathway associated with cisplatin-induced 
apoptotic signaling, the suppression of ERK phosphorylation in Prx I (-/-) cells could 
result in reduced apoptosis. Further studies are necessary to elucidate the upstream and 
downstream components of the cisplatin-induced apoptotic cascade and to define the 
cross-talk point of Prx I’s action on the signaling pathways.
In conclusion, our study revealed that Prx I plays an anti-apoptotic role by 
reducing cisplatin-induced damage in MEFs. The mechanism underlying this 
phenomenon mainly involves modulating the apoptosis signal relayed through MAPKs. 
It is not yet clear what the main target of Prx I is in the apoptotic pathway; nevertheless, 
our results identify Prx I as an important factor in the protection of cells from cisplatin 
10
damage. This finding highlights the potential usefulness of Prx I as either a protective 
factor that could ameliorate cisplatin-induced side effects, such as renal failure, or as an 
exacerbating factor in the resistance of malignant tumors associated with oral cancers to 
cisplatin.
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Legends to Figures
Figure 1. Prx I-deficient (Prx I (-/-)) MEFs are more sensitive than wild-type (Prx I 
(+/+)) MEFs to cisplatin treatment. Prx I (-/-) and Prx I (+/+) MEFs were seeded into 
96-well plates and treated with different doses of cisplatin for 72 hours. Cell viability 
was assessed using the MTT colorimetric assay, as described in Materials and Methods. 
Prx I (-/-) and Prx I (+/+) MEFs were maintained in medium containing 10% FBS for 
24 hours, followed by incubation with cisplatin (0, 2.5, 5.0, 10.0, and 25.0 g/ml). 
Values are the means ± SD from five measurements. P < 0.001 (***) compared with Prx 
I (+/+) cells.
Figure 2. Enhanced apoptosis of Prx I (-/-) MEFs following treatment with cisplatin. A. 
Prx I (+/+) and Prx I (-/-) MEFs were cultured in medium containing 10% FBS for 24 
hours, followed by incubation with 5.0 g/ml cisplatin for 24, 48, or 72 hours. Cells 
were doubly stained for annexin V and PI, and were analyzed by FACS. The cells in the 
lower-right quadrant (annexin V-positive/PI-negative) were in early apoptosis, those 
cells in the lower-left quadrant (annexin V-negative /PI-negative) were alive, those in 
the upper-right quadrant (annexin V-positive/PI-positive) were in late apoptosis, and 
cells in the upper-left quadrant (annexin V-negative/PI-positive) were damaged. B. Prx I 
(-/-) MEF cells treated with cisplatin showed increased frequencies of apoptotic cells 
compared with the Prx I (+/+) MEF cells. The percentage of cells in the upper- and 
lower-right quadrants was used as the apoptosis ratio. Values are the means ± SD from 
five independent experiments. P < 0.01 (**), P < 0.001 (***) compared with Prx I (+/+) 
cells.
Figure 3. Cisplatin-induced activation of MAPKs in Prx I (+/+) and Prx I (-/-) MEFs. 
MEFs were treated with 50 g/ml cisplatin for the indicated times. The cell proteins 
were separated by 10% SDS-PAGE, and analyzed by immunoblotting with anti-MAPK 
(A, p38 MAPK; C, JNK; and E, ERK1/2) antibodies. The fold increase in 
phosphorylated MAPK was determined from the band density of the 
phospho-MAPK/total MAPK. p-p38, phosphorylated p38; p38, total p38; actin, the 
loading control; Prx I, Prx I expression. B, Quantification of the p38 phosphorylation in 
12
Prx I (+/+) and Prx I (-/-) MEFs. C and D, The phosphorylation and quantification of 
JNK. Panels E and F, the phosphorylation and quantification of ERK1/2. Values are 
expressed as the means  SD of five independent experiments.
Figure 4. Effect of MAPK inhibitors on cisplatin-induced apoptosis. Prx I (-/-) and Prx I 
(+/+) MEFs were induced to undergo apoptosis by cisplatin (Cis; 50 g/ml) in the 
absence or presence of MAPK-specific inhibitors. The inhibitors were added to the cells 
in DMEM medium 30 min before the addition of cisplatin. After 24 hours, the cells 
were stained with FITC-conjugated annexin V and PI. The percentage of 
annexin-V/PI-stained cells was determined by flow cytometry. A, Representative results 
of cisplatin-induced apoptosis in the presence of SB203580 (SB: p38 inhibitor), 
SP600125 (SP: JNK inhibitor), and PD98059 (PD: ERK inhibitor). B, Proportion of 
apoptotic cells in each treatment condition and in untreated control cells. The 
percentage of cells in the upper- and lower-right quadrants was used as the apoptosis 
ratio. Values are expressed as the means ± SD of five independent experiments. P < 0.01 
(**), P < 0.001 (***) compared with Prx I (+/+) MEFs. P < 0.05 (†), P < 0.01 (††), P < 
0.001 (†††) compared with cisplatin-treated Prx I (+/+) MEFs. P < 0.05 (#), P < 0.01 
(##) compared with cisplatin-treated Prx I (-/-) MEFs.
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Legend to supplementary figures.
Supplementary figure 1. Cisplatin induces Prx I expression. Prx I (+/+) MEFs were 
cultured in medium containing 10% FBS for 24 hours, followed by incubation with 50 
g/ml cisplatin for 0, 8, or 16 hours. Cells were analyzed by immunoblotting with an 
anti-Prx I polyclonal antibody. Prx I expression was induced by cisplatin and peaked at 
8 hr of treatment.
Supplementary figure 2. Effects of MAPK-specific inhibitors on Prx I (-/-) and Prx I 
(+/+) MEFs. Apoptosis was induced in Prx I (-/-) and Prx I (+/+) MEFs by cisplatin
treatment (50 g/ml) in the absence or presence of MAPK-specific inhibitors. The 
inhibitors were added to the cells in DMEM medium 30 min before the addition of 
cisplatin. After 3 hours, the cells were collected and analyzed by immunoblotting. The 
figure shows representative results of cisplatin-induced phosphorylation in the presence 
or absence of PD98059 (ERK inhibitor), SP600125 (JNK inhibitor), or SB203580 (p38 
inhibitor). PD98059 and SP600125 inhibited the phosphorylation of ERK1/2 and JNK, 
respectively. SB203580 did not inhibit the phosphorylation of p38, because SB203580 
has no significant effect on the activities of MAPKs, including p38 MAPK. 1
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